case_images: PMC11025443_01
case_images: Comparative PET-CT scans before (20 May 2021) and after (9 March 2022) PARP inhibitor therapy initiation, demonstrating complete response to treatment. (a) Before treatment sagittal section (SUVmax = 6.3); (b) during treatment sagittal section (no suspicious uptake); (c) before treatment coronal section (SUVmax = 6.3); (d) and during treatment coronal section (no suspicious uptake).
case_images: 10.1177_17588359241245283-fig1.jpg
case_images: PMC11025443_01_10.1177_17588359241245283-fig1.jpg
case_images: fig1-17588359241245283
case_images: However, in May 2021, 1 month after completing chemotherapy, the patient presented a new lesion in the left obturator internus muscle of 2.5 x 1.5 cm with an SUVmax of 6.3, consistent with disease relapse [Figure 1(a) and (c)]. September 2021 to April 2022 due to fatigue and dizziness. Subsequent PET-CT scans conducted in November 2021 and March 2022 revealed a complete response to treatment with no suspicious uptake [Figure 1(b) and (d)].